Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yanlu Rukang is a traditional Chinese medicine (TCM) formulation primarily indicated for the treatment of mammary gland hyperplasia (also known as cyclomastopathy or benign breast hyperplasia). It is available in capsule form and is recognized under the approval number Z20025379 in China. The preparation contains multiple herbal ingredients, with bergenin being one of the notable components. The mechanism of action is not fully elucidated but is believed to involve modulation of endocrine function and anti-inflammatory effects typical of TCM approaches to benign breast disorders. There are also reports suggesting its use in other conditions such as Peyronie's disease (induration of penis), though its primary indication remains mammary gland hyperplasia[1][2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yanlu Rukang.